Understanding genetic factors affecting survival after blood stem cell transplants
Immunogenetics of Outcomes Disparities After Allogeneic HCT
This study is looking at how genetic differences related to ancestry can affect the success of blood cancer treatments using stem cell transplants, with the goal of helping doctors choose better donors and improve survival rates for all patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11066498 on NIH RePORTER |
What this research studies
This research investigates the genetic differences that contribute to survival disparities among patients undergoing hematopoietic cell transplantation (HCT) for blood cancers. By focusing on ancestry-specific genetic features, the study aims to identify key factors that influence transplant outcomes and the risk of cancer relapse. The researchers will analyze the NKG2 ligand and receptor variations that may affect survival rates across different racial and ethnic groups. This work seeks to enhance donor selection and patient risk assessment to improve outcomes for all transplant patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients of African, Hispanic, Asian, and Caucasian American descent who are undergoing or have undergone hematopoietic cell transplantation.
Not a fit: Patients who do not fall into the specified racial or ethnic groups or those who are not undergoing blood stem cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more equitable survival rates for patients of diverse ancestries undergoing blood stem cell transplants.
How similar studies have performed: Previous research has shown that addressing genetic disparities can improve outcomes in transplant patients, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Petersdorf, Effie W — Fred Hutchinson Cancer Center
- Study coordinator: Petersdorf, Effie W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.